Preoperative bevacizumab does not increase complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

BACKGROUND: Preoperative bevacizumab has been reported to increase postoperative complication risk following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). We sought to review our experience with preoperative bevacizumab in patients undergoing CRS/HIPEC for peritone...

Descripción completa

Detalles Bibliográficos
Autores principales: King, Bradley H., Baumgartner, Joel M., Kelly, Kaitlyn J., Marmor, Rebecca A., Lowy, Andrew M., Veerapong, Jula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714141/
https://www.ncbi.nlm.nih.gov/pubmed/33270763
http://dx.doi.org/10.1371/journal.pone.0243252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714141/
https://www.ncbi.nlm.nih.gov/pubmed/33270763
http://dx.doi.org/10.1371/journal.pone.0243252

Ejemplares similares